Research programme: immunomodulatory nanoparticles - Selecta Biosciences

Drug Profile

Research programme: immunomodulatory nanoparticles - Selecta Biosciences

Alternative Names: SEL-201; tSVP

Latest Information Update: 17 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selecta Biosciences
  • Developer Selecta Biosciences; Uniformed Services University of the Health Sciences
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 09 Dec 2013 Pharmacodynamics data from a preclinical trial in Haemophilia A presented at the 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2013)
  • 09 Dec 2013 Preclinical trials in Haemophilia A in USA (Parenteral)
  • 10 Jun 2011 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top